[Breast cancer and the hand-foot syndrome]

Claire Llambrich; Marie-Christine Falcou; Yann De Rycke; Paul Cottu; Sylvie Carrié; Malika Medjbari

[Breast cancer and the hand-foot syndrome]

Soins. 2012 Jun:(766):25-8.

[Article in French]

Authors

Claire Llambrich¹, Marie-Christine Falcou, Yann De Rycke, Paul Cottu, Sylvie Carrié, Malika Medjbari

Affiliation

¹ Hôpital de jour, département d'oncologie médicale, Institut Curie, Paris. claire.llambrichmolines@curie.net

PMID: 22870762

Abstract

Regarding patients being treated for breast cancer and on oral capecitabine, the main side effect is the hand-foot syndrome (HFS), or Palmar-Plantar Erythrodysesthesia (PPE).). This could be inconvenient or even debilitating depending on the grade. The Day Care Centre at the Institut Curie in Paris (75) conducted a prospective study on patients treated with oral capecitabine for advanced breast cancer, to assess the rate of appearance of the hand-foot syndrome and the impact of paramedical follow-up on the occurrence of this side effect.

Publication types

English Abstract

MeSH terms

Adult
Aged
Aged, 80 and over
Antimetabolites, Antineoplastic / administration & dosage
Antimetabolites, Antineoplastic / adverse effects*
Breast Neoplasms / drug therapy*
Capecitabine
Deoxycytidine / administration & dosage
Deoxycytidine / adverse effects
Deoxycytidine / analogs & derivatives*
Female
Fluorouracil / administration & dosage
Fluorouracil / adverse effects
Fluorouracil / analogs & derivatives*
Hand-Foot Syndrome / etiology*
Humans
Middle Aged
Paris
Prospective Studies
Risk Factors

Substances

Antimetabolites, Antineoplastic
Deoxycytidine
Capecitabine
Fluorouracil